Sclerosis
9
1
1
6
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 9 trials
100.0%
+13.4% vs benchmark
0%
0 trials in Phase 3/4
33%
2 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 6 completed trials
Clinical Trials (9)
Aerobic Exercise for Remyelination in Multiple Sclerosis
Acceptability of Exoskeleton Assisted Walking for Persons With Mobility Issues Due to Multiple Sclerosis
A Study of RD06-04 in Patients With Active Autoimmune Diseases
Effects of Individualized Training to Reduce Fatigue in Patients With Newly and Advanced Diagnosed Multiple Sclerosis
Power Training in Older Multiple Sclerosis Patients
Scleroderma: Cyclophosphamide or Transplantation
Assessment of Language Disorders in Multiple Sclerosis Patients
A Longitudinal Study of Amyotrophic Lateral Sclerosis (ALS) Biomarkers
SCOT Scleroderma Treatment Alternative Registry (STAR Registry)